Literature DB >> 18641367

Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.

Steffan T Nawrocki1, Jennifer S Carew, Kirsteen H Maclean, James F Courage, Peng Huang, Janet A Houghton, John L Cleveland, Francis J Giles, David J McConkey.   

Abstract

The histone deacetylase inhibitor SAHA enhances cell death stimulated by the proteasome inhibitor bortezomib (BZ) by disrupting BZ-induced aggresome formation. Here we report that Myc regulates the sensitivity of multiple myeloma (MM) cells to BZ + SAHA-induced cell death. In MM cells, Myc expression directly correlated with intracellular ER content, protein synthesis rates, the percentage of aggresome-positive cells, and the sensitivity to BZ + SAHA-induced cell death. Accordingly, Myc knockdown markedly reduced the sensitivity of MM cells to BZ + SAHA-mediated apoptosis. Furthermore, activation of Myc was sufficient to provoke aggresome formation and thus sensitivity to BZ + SAHA, and these responses required de novo protein synthesis. BZ + SAHA-mediated stimulation of apoptosis includes the induction of the proapoptotic BH3-only protein Noxa as well as endoplasmic reticular stress, a disruption of calcium homeostasis, and activation of capase-4. Finally, knockdown studies demonstrated that both caspase-4 and Noxa play significant roles in Myc-driven sensitivity to BZ + SAHA-induced apoptosis. Collectively, our results establish a mechanistic link between Myc activity, regulation of protein synthesis, increases in HDAC6 expression and aggresome formation, induction of Noxa, and sensitivity to BZ + SAHA-induced apoptosis. These data suggest that MM patients with elevated Myc activity may be particularly sensitive to the BZ + SAHA combination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18641367      PMCID: PMC2556625          DOI: 10.1182/blood-2007-12-130823

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

Review 1.  The role of c-myc in cellular growth control.

Authors:  E V Schmidt
Journal:  Oncogene       Date:  1999-05-13       Impact factor: 9.867

2.  Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.

Authors:  H Avet-Loiseau; F Gerson; F Magrangeas; S Minvielle; J L Harousseau; R Bataille
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

3.  c-Myc enhances protein synthesis and cell size during B lymphocyte development.

Authors:  B M Iritani; R N Eisenman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

4.  c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL.

Authors:  Kirsteen H Maclean; Ulrich B Keller; Carlos Rodriguez-Galindo; Jonas A Nilsson; John L Cleveland
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

5.  Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.

Authors:  Simon Williams; Curtis Pettaway; Rendu Song; Christos Papandreou; Christopher Logothetis; David J McConkey
Journal:  Mol Cancer Ther       Date:  2003-09       Impact factor: 6.261

Review 6.  Myc pathways provoking cell suicide and cancer.

Authors:  Jonas A Nilsson; John L Cleveland
Journal:  Oncogene       Date:  2003-12-08       Impact factor: 9.867

7.  The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

Authors:  Chunrong Yu; Mohamed Rahmani; Daniel Conrad; Mark Subler; Paul Dent; Steven Grant
Journal:  Blood       Date:  2003-07-31       Impact factor: 22.113

8.  Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts.

Authors:  Steffan T Nawrocki; Christiane J Bruns; Matthew T Harbison; Richard J Bold; Bridget Sweeney Gotsch; James L Abbruzzese; Peter Elliott; Julian Adams; David J McConkey
Journal:  Mol Cancer Ther       Date:  2002-12       Impact factor: 6.261

9.  A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.

Authors:  Zirong Li; Sara Van Calcar; Chunxu Qu; Webster K Cavenee; Michael Q Zhang; Bing Ren
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

10.  Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.

Authors:  Ann-Hwee Lee; Neal N Iwakoshi; Kenneth C Anderson; Laurie H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-05       Impact factor: 11.205

View more
  45 in total

1.  KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.

Authors:  Sudha Mannava; DaZhong Zhuang; Jayakumar R Nair; Rajat Bansal; Joseph A Wawrzyniak; Shoshanna N Zucker; Emily E Fink; Kalyana C Moparthy; Qiang Hu; Song Liu; Lawrence H Boise; Kelvin P Lee; Mikhail A Nikiforov
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

2.  Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

Authors:  Loredana Santo; Teru Hideshima; Andrew L Kung; Jen-Chieh Tseng; David Tamang; Min Yang; Matthew Jarpe; John H van Duzer; Ralph Mazitschek; Walter C Ogier; Diana Cirstea; Scott Rodig; Homare Eda; Tyler Scullen; Miriam Canavese; James Bradner; Kenneth C Anderson; Simon S Jones; Noopur Raje
Journal:  Blood       Date:  2012-01-19       Impact factor: 22.113

3.  Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.

Authors:  Rekha Rao; Srilatha Nalluri; Warren Fiskus; Andrew Savoie; Kathleen M Buckley; Kyungsoo Ha; Ramesh Balusu; Atul Joshi; Veena Coothankandaswamy; Jianguo Tao; Eduardo Sotomayor; Peter Atadja; Kapil N Bhalla
Journal:  Clin Cancer Res       Date:  2010-07-20       Impact factor: 12.531

Review 4.  Novel therapies in MM: from the aspect of preclinical studies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Int J Hematol       Date:  2011-09-01       Impact factor: 2.490

5.  Proteasome inhibitors in cancer therapy.

Authors:  Lisa J Crawford; Brian Walker; Alexandra E Irvine
Journal:  J Cell Commun Signal       Date:  2011-01-31       Impact factor: 5.782

Review 6.  The integrated stress response and proteotoxicity in cancer therapy.

Authors:  David J McConkey
Journal:  Biochem Biophys Res Commun       Date:  2017-02-03       Impact factor: 3.575

Review 7.  The Tao of myeloma.

Authors:  Lawrence H Boise; Jonathan L Kaufman; Nizar J Bahlis; Sagar Lonial; Kelvin P Lee
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

8.  Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.

Authors:  Justin T Babcock; Hoa B Nguyen; Yujun He; Jeremiah W Hendricks; Ronald C Wek; Lawrence A Quilliam
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

9.  Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.

Authors:  T Watanabe; K Nagase; M Chosa; K Tobinai
Journal:  Br J Cancer       Date:  2010-10-19       Impact factor: 7.640

10.  Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.

Authors:  Jennifer S Carew; Ernest C Medina; Juan A Esquivel; Devalingam Mahalingam; Ronan Swords; Kevin Kelly; Hui Zhang; Peng Huang; Alain C Mita; Monica M Mita; Francis J Giles; Steffan T Nawrocki
Journal:  J Cell Mol Med       Date:  2010-10       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.